Take our post-test to claim CME credits.
To read a companion newsletter click here.
Elexacaftor/tezacaftor/ivacaftor — the newly approved triple combination CFTR modulator therapy. What are the benefits? For which patients? What are the potential adverse effects? Who’s most likely to receive them?
In this issue, Dr. Scott Sagel from the Breathing Institute at the Children’s Hospital Colorado, part of the University of Colorado’s Anschutz Medical Campus, takes us to the clinic to discuss some answers.
Podcast (ecystic): Play in new window | Download
Subscribe: Apple Podcasts | Android | RSS